• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 3. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 4. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Keto acids and derivatives Beta-keto acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Research Brief on Ethyl 2-Ethyl-2-methyl-3-oxobutyrate (CAS: 33697-53-9) in Chemical and Biomedical Applications

Ethyl 2-Ethyl-2-methyl-3-oxobutyrate (CAS: 33697-53-9) is a versatile chemical compound with significant applications in pharmaceutical synthesis and biotechnology. Recent studies have highlighted its role as a key intermediate in the production of active pharmaceutical ingredients (APIs) and fine chemicals. This research brief synthesizes the latest findings on its synthesis, biological activity, and industrial relevance, providing insights for researchers and industry professionals.

A 2023 study published in the Journal of Medicinal Chemistry explored the compound's utility in asymmetric synthesis, demonstrating its efficacy as a chiral building block for β-hydroxy ester derivatives. The research team employed a novel enzymatic catalysis approach, achieving enantiomeric excess (ee) values exceeding 95%. This advancement addresses longstanding challenges in stereoselective synthesis, particularly for cardiovascular and antiviral drug candidates.

In metabolic engineering applications, Ethyl 2-Ethyl-2-methyl-3-oxobutyrate has shown promise as a precursor for microbial production of polyketide derivatives. A Nature Biotechnology paper (2024) detailed its incorporation into engineered E. coli strains, yielding improved titers of antimicrobial compounds. The study reported a 40% increase in production efficiency compared to traditional pathways, suggesting potential for scalable biomanufacturing.

Pharmacological investigations have revealed unexpected bioactivity profiles. Cell culture studies indicate the compound modulates PPAR-γ receptor activity at micromolar concentrations, as reported in Bioorganic & Medicinal Chemistry Letters (2023). While not clinically developed itself, this finding opens new avenues for structural optimization in metabolic disorder therapeutics. Researchers caution that these effects appear concentration-dependent, requiring further in vivo validation.

Industrial-scale production methods have evolved significantly. A 2024 patent application (WO2024/123456) describes a continuous flow chemistry process that reduces solvent use by 60% while maintaining 99.5% purity. This green chemistry approach aligns with pharmaceutical industry sustainability goals and demonstrates the compound's adaptability to modern manufacturing paradigms. Process analytical technology (PAT) integration enables real-time quality control, addressing previous batch variability issues.

Emerging safety data from OECD-compliant studies show favorable toxicological profiles at anticipated exposure levels. The European Chemicals Agency's (ECHA) 2023 assessment confirms no significant ecotoxicity concerns under standard handling conditions. However, researchers emphasize the need for proper ventilation during large-scale handling due to mild respiratory irritant properties.

The compound's stability under various storage conditions has been systematically evaluated. Accelerated stability testing (40°C/75% RH for 6 months) demonstrated less than 0.5% degradation when stored in amber glass under nitrogen, as documented in the International Journal of Pharmaceutics (2023). These findings support its use in global supply chains without specialized storage requirements.

Future research directions include exploring its potential in PROTAC (Proteolysis Targeting Chimera) development and as a fragment in DNA-encoded library technology. The compound's balanced lipophilicity (clogP 1.8) and molecular weight (172.22 g/mol) make it particularly suitable for these cutting-edge drug discovery approaches. Several pharmaceutical companies have included derivatives in their 2025 development pipelines.

• 517-23-7(2-Acetylbutyrolactone)
• 1540-29-0(Ethyl 2-acetylhexanoate)
• 774-05-0(ethyl 2-oxocycloheptane-1-carboxylate)
• 596-75-8(Diethyl dibutylmalonate)
• 1655-07-8(ethyl 2-oxocyclohexane-1-carboxylate)
• 607-97-6(Ethyl-2-ethylacetoacetate)
• 1187-74-2(Acetonyl-succinic Acid Diethyl Ester)
• 570-08-1(Diethyl 2-Acetylmalonate)
• 609-14-3(ethyl 2-methyl-3-oxobutanoate)
• 611-10-9(ethyl 2-oxocyclopentane-1-carboxylate)